drugset
drugset / Trial / NCT03947489

Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions

NCT03947489 ↗

Phase 1 Completed 38 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions

Timeline

Start
2019-03-04
Primary completion
2019-05-06
Completion
2019-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarpogrelate Small molecule 300 mg Oral

Indications

No indication recorded.